Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

Aurora Cannabis Approved To Ship To Germany

Published 2017-09-27, 11:49 a/m
Updated 2023-07-09, 06:32 a/m

Aurora Cannabis Inc. (TO:ACB) announced recently that it has received all the required permits to ship dried cannabis flower from Canada to Germany, enabling the company to enter into the German medical cannabis market through its wholly-owned subsidiary Pedanios, Germany’s leading medical cannabis distributor. Aurora is now in receipt of a Health Canada-issued export permit, as well as provisional import status from the German Bundesopiumstelle (Federal Narcotics Bureau), to import medical cannabis products into Germany. Import permits for additional product have been secured, and ongoing, regular shipments are scheduled. Post the announcement, Aurora Cannabis shares climbed 2.5%.

On Sept. 18, Aurora shipped 50 kilograms of dried cannabis from its facility in Mountain View County, Alta., to Berlin-based Pedanios. Upon delivery to Pedanios, the product will be distributed to a network of more than 1,500 pharmacies across Germany, a country of more than 82 million people. Germany currently represents the largest single federally-legal medical cannabis market in the world, and is experiencing a significant shortage of supply. Through Pedanios, Aurora Cannabis plans to become a top producer and supplier of medical cannabis products in Germany, as well as other European Union markets.

When all of Canada’s licensed marijuana producers were busy capturing the domestic recreational markets, Aurora Cannabis had a different game plan with international plans. In May 2017, Aurora acquired German cannabis firm Pedanios. Legal cannabis is new to Germany, since March 2017.

This international expansion represents a huge milestone for Aurora Cannabis and marks the first step in unlocking the future potential markets in the EU. Additionally, the expansion strongly validates Aurora’s acquisition of Pedanios as one of the most significant strategic transactions to date in the cannabis industry.

Pedanios, over the last 90 days leading up to its acquisition by Aurora Cannabis, had achieved cash flow positive operations, with gross revenues of about C$1.15 million, and costs of approximately C$1 million. Revenues for May, up to and including May 26, 2017, were approximately C$0.5 million, reflecting a 410% increase in the daily sales pace as compared with the average for the eight months prior to the introduction of the new law, and an increase over the April and March 2017 averages of 70% and 108%, respectively.

Aurora Cannabis shares have climbed over 15% during the past month and are currently trading at Price to TTM Sales of 76.36x and Price to Book of 5.91x.

Disclosure: Neither the author nor any of the principals at SmallCapPower, or their family members, own shares in the company mentioned above.

To read the original text.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.